Advertisement

Testing for Malignant Hyperthermia in North America and Australia

  • Henry Rosenberg
Conference paper

Abstract

There are 14 biopsy centers for malignant hyperthermia (MH) in the United States and Canada, and 3 in Australia. In recent years 3 biopsy centers in North America have closed for funding reasons or because the center director changed the emphasis of his/her activities.

Keywords

Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy Malignant Hyperthermia Malignant Hyperthermia Malignant Hyperthermia Susceptibility 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Larach MG (1989) Standardization of the caffeine halothane muscle contracture test. Anesth Analg 69: 511–515PubMedCrossRefGoogle Scholar
  2. 2.
    Larach MH, Localio R, Allen GC, et al (1994) A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 80: 771PubMedCrossRefGoogle Scholar
  3. 3.
    Larach MG, Landis JR, Bunn JS, et al (1992) Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture rsponses. Anesthesiology 76: 16–24PubMedCrossRefGoogle Scholar
  4. 4.
    Larach MG, Landis JR, Shirk SI, et al (1992) Prediction of malignant hyperthermia susceptibility in man: improving sensitivity of the caffeine halothane contracture test. Anesthesiology 77: A1052CrossRefGoogle Scholar
  5. 5.
    Wedel DJ, Nelson TE (1994) Malignant hyperthermia-diagnostic dilemma: False-negative contracture responses with halothane and caffeine alone. Anesth Analg 78: 787–785Google Scholar
  6. 6.
    O’Flynn RP, Shutack JG, Rosenberg H, et al (1994) Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. Anesthesiology 80: 1228–1295PubMedCrossRefGoogle Scholar
  7. 7.
    Wappler F, Roewer N, Lenzen C, et al (1994) High-purity ryanodine and 9,21dehydroryanodine for in vitro diagnosis of malignant hyperthermia in man. Br J Anaesth 72: 240–242PubMedCrossRefGoogle Scholar

Further Reading

  1. Fletcher JE (1994) Current laboratory methods for the diagnosis of malignant hyperthermia susceptibility. In: Levitt RC (ed) Temperature regulation during anesthesia. Anesthesiology clinics of North America, vol. 12. Saunders, Philadelphia, pp 553–570Google Scholar

Copyright information

© Springer-Verlag Tokyo 1996

Authors and Affiliations

  • Henry Rosenberg
    • 1
  1. 1.MCP/Hahnemann UniversityPhiladelphiaUSA

Personalised recommendations